Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07709429

Qigong Exercise for Muscles Strength and Quality of Life in Colorectal Cancer Patients Undergoing Chemotherapy

The purpose of this study is to evaluate therapeutic effect of Qigong for muscle strength and quality of life in colorectal cancer patients undergoing chemotherapy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

35 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Muscle weakness and fatigue are prevalent side effects experienced by patients undergoing chemotherapy for colorectal cancer. These symptoms can significantly impact daily functioning and overall quality of life. Finding effective treatments for this condition is crucial to improving patient outcomes and quality of life.

Qigong serves as a holistic exercise modality that not only strengthens muscles but also elevates the overall quality of life. Its gentle movements make it accessible to a wide range of individuals, including those undergoing rehabilitation or managing chronic health issues.

Furthermore the need of this study is developed from lack in the quantitative knowledge and information in the published studies about the effect of Qigong on muscle strength and quality of life in colorectal cancer patients undergoing chemotherapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ranges between 35 and 55 years.
  • Male & female patients will participate in the study.
  • All patients with colorectal cancer undergoing chemotherapy.
  • All patients enrolled to the study will have their informed consent.
  • The patients will be instructed to report any side effects during the management.

Exclusion criteria

  • Presence Patients with psychological disturbance or mental illness.
  • Cardiopulmonary disease.
  • Hypotensive patients.
  • Nerve, muscle, or joint disease, or other malignant tumors affecting movement.
  • Autoimmune disease.

Treatment and study plan

Qigong Exercise

Other

Participants will receive a supervised Baduanjin Qigong exercise program combined with conventional exercises, including pain-free range-of-motion exercises, low-intensity walking, and physical therapy education. The intervention will be conducted three times weekly for 12 weeks under physiotherapist supervision, while participants continue their prescribed chemotherapy and routine medical follow-up.

Conventional Exercise Program

Other

Participants in this arm will receive a conventional exercise program consisting of pain-free range-of-motion exercises for the shoulder, elbow, wrist, hip, knee, and ankle joints, low-intensity walking, and physical therapy education to maintain daily activities. The intervention will be administered for 12 weeks, with three sessions per week. Participants will continue their prescribed chemotherapy and routine outpatient medical follow-up throughout the study and will not participate in any additional structured exercise program during the intervention period.

Primary outcomes

  1. Muscle Strength

    Time frame: 12 weeks

    Muscle strength of the upper and lower limbs will be assessed using the Lafayette Hand-Held Dynamometer. Muscle strength will be quantified as the maximum isometric force generated by the tested muscle groups, with higher values indicating greater muscle strength.

Secondary outcomes

  1. Health-Related Quality of Life

    Time frame: 12 weeks

    Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The questionnaire evaluates multiple domains of physical and mental health, with domain scores ranging from 0 to 100. Higher scores indicate better health-related quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Khadra Mohammed Ali, PhD

CONTACT

Shrouk Mohamed Reda Abd Elaliem, M.Sc

CONTACT

[email protected]

+20 12 71384571

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 16, 2026
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.